Market Overview
“The Global Metered Dose Inhaler Devices Market is expected to grow at a high CAGR during the forecasting period (2021-2028).”

A metered dose inhaler (MDI) is a pressurized inhaler that delivers medication by using a propellant spray. It is widely useful for people with respiratory disorders like asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis, and emphysema.

In recent years, there has been a rise in the prevalence of the diseases of the respiratory system such as chronic obstructive pulmonary diseases, asthma, chronic respiratory diseases, and others. According to WHO, more than 3 million people die each year from COPD worldwide while 235 million have asthma.

As a result, there has been a rise in awareness among people about the advanced respiratory devices that have beneficial features over the traditional treatment methods, thus propelling the market growth. However, MDIs, release environmentally-hazardous gases, namely chlorofluorocarbon (CFC) and hydrofluoroalkanes (HFA), which is negatively impacting the growth of the MDI market.

Download free sample:

Market Drivers and Restraints

The Global Metered Dose Inhaler Devices market report segments the market by product type, by technology type, by application, and by region.

Based on product type, the market further bifurcated into the manually-actuated pressurized inhaler and breath-actuated pressurized inhaler.

Based on application, the market is segmented into the chronic obstructive pulmonary disease, asthma, chronic bronchitis, and emphysema. Out of these, asthma is expected to hold the maximum share percentage.

Regarding the distribution channel, the market is categorized into retail pharmacies, hospital pharmacies, and e-commerce. Retail pharmacies are expected to hold the maximum market share due to rise in the over-the-counter sale of MDIs.

Regional Analysis

Geographically, the market is segmented into five major regions, namely North America, South America, Europe, Asia Pacific, and RoW. The demand for metered dose inhalers is dominated by North America, with the US holding the maximum market share.

Asia-Pacific represents a massive opportunity for market expansion due to the increasing prevalence of asthma that has resulted from high levels of air pollution, rapid urbanization, the rise in smoking population, and changing lifestyle.

Market Segmentation Analysis

By Product Type

  • Manually-actuated pressurized inhalers
  • Breath-actuated pressurized inhalers

By Application

  • Chronic Obstructive Pulmonary Disease
  • Asthma
  • Chronic Bronchitis
  • Emphysema

By Distribution Channel

  • Retail pharmacies
  • Hospital pharmacies
  • E-commerce

By Region

  • Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific)
  • Europe (Germany, France, The UK, Italy, Spain, Rest of Europe)
  • North America (The USA, Canada, Mexico)
  • South America (Brazil, Argentina, Rest of South America)
  • Rest of the World

View full report:

Competitive Landscape

The following companies in the Metered Dose Inhaler Devices market – AstraZeneca plc, Boehringer Ingelheim GmbH, F Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Merck & Co. Inc., Novartis AG, Pfizer, and Cipla Ltd.

Trending Topics:

Spirometers Market

Tumor Ablation Market

Urology Devices Market

Phototherapy Equipment Market

Pen Needles Market

Tags: Novartis AG, Metered Dose Inhaler Devices Market, Metered Dose Inhaler Devices, Emphysema, AstraZeneca plc, Boehringer Ingelheim GmbH, Merck & Co. Inc, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Chronic Obstructive Pulmonary Disease, Cipla Ltd, Pfizer, Asthma

See Campaign:
Contact Information:
Sai Kiran Sales Manager at DataM Intelligence Email: [email protected] Tel: +1 877 441 4866 Website:

PR-Wirein, Reportedtimes, Menafn, iCN Internal Distribution, Extended Distribution, Research Newswire, English